Understanding how intestinal immune cells contribute to the development and activity of IgA nephropathy

The role of intestinal mucosal B cells in the pathogenesis and activity of IgA nephropathy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN11448420

Enrollment

Registered

2026-04-22

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy Urological and Genital Diseases

Interventions

This is an observational quantitative cross-sectional study including patients with biopsy-proven IgA nephropathy and controls from the general population. Blood, urine, and intestinal biopsy samples

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Cases – IgAN group: 1. Adults (=18 years) 2. Biopsy-proven IgA nephropathy 3. eGFR =45 ml/min/1.73 m² 4. Proteinuria <1 g/day 5. Indication for colonoscopy (anemia, change in bowel habits, abdominal pain, positive fecal occult blood test) Controls: 1. Adults (=18 years) 2. Individuals from general population undergoing screening colonoscopy 3. Positive fecal occult blood test 4. No pathological findings in colonoscopy (no polyps, tumors, inflammation)

Exclusion criteria

Exclusion criteria: 1. Age <18 years 2. Pregnancy or breastfeeding 3. Secondary IgA nephropathy 4. IgA vasculitis 5. Liver disease 6. Alcoholism 7. Type 1 or type 2 diabetes mellitus 8. Chronic inflammatory diseases 9. Malignancy 10. Acute myocardial infarction or stroke within the last 6 months 11. Active gastrointestinal bleeding For control group: polyps, tumors, or inflammatory changes detected during colonoscopy

Countries

Latvia

Contacts

Public ContactMikus Saulite

mikus.saulite@stradini.lv+371 (0)67069286

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 30, 2026